PP
JAZZ icon

Pacifica Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pacifica Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1
Closed – – 488
2022
Q2 		$0 Hold
1
– – ﹤0.01% 499
2022
Q1 		$0 Hold
1
– – ﹤0.01% 490
2021
Q4 		$0 Hold
1
– – ﹤0.01% 499
2021
Q3 		$0 Hold
1
– – ﹤0.01% 497
2021
Q2 		$0 Buy
+1
New +$173 ﹤0.01% 482

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Pacifica Partners's JAZZ Position: Q3 2022 in Review

Pacifica Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 1 share.

Pacifica Partners first reported a position in JAZZ in Q2 2021 and held it in 5 quarters. The position peaked at $0 in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Pacifica Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Pacifica Partners sold 1 Jazz Pharmaceuticals share in Q3 2022.
  • Pacifica Partners first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Pacifica Partners's Jazz Pharmaceuticals position peaked at $0 in Q2 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Pacifica Partners's 13F filing for Q3 2022, filed 14 Oct 2022.